Complete Remission of Recurrent Glioblastoma Multiforme Following Local Infusions of Lymphokine Activated Killer Cells. Case Report

Overview

Journal Acta Neurochir (Wien)

Specialty Neurosurgery

Date 1989 Jan 1

PMID 2549767

Citations 8

Authors

H Naganuma

R Kimurat

A Sasaki

A Fukamachi

H Nukui

K Tasaka

Affiliations

Soon will be listed here.

Abstract

We report the case of a 26-year-old man in whom glioblastoma multiforme had recurred six months following a subtotal resection. Despite radiotherapy and a course of interferon beta and ACNU, the tumour increased in size (to 3 cm) and there was neurological deterioration. Treatment was then initiated with LAK cells, together with ACNU and interferon beta. After three courses of LAK cells, tumour size was markedly reduced, and at about six months the tumour had nearly disappeared on computed tomographic (CT) scans. At one year, and after nine courses of LAK cell therapy (total dose of 2.7 x 10(9) cells) infused via an Ommaya reservoir and supplemented by ACNU and interferon beta, the tumour has disappeared and the patient is considered to be in complete remission since 6 months. This marked response is thought to be due chiefly to LAK cell therapy. The relatively low dose administered was well-tolerated.

Citing Articles

Nonlinear modelling of cancer: bridging the gap between cells and tumours.

Lowengrub J, Frieboes H, Jin F, Chuang Y, Li X, Macklin P Nonlinearity. 2010; 23(1):R1-R9.

PMID: 20808719 PMC: 2929802. DOI: 10.1088/0951-7715/23/1/r01.

Computer simulation of glioma growth and morphology.

Frieboes H, Lowengrub J, Wise S, Zheng X, Macklin P, Bearer E Neuroimage. 2007; 37 Suppl 1:S59-70.

PMID: 17475515 PMC: 2243223. DOI: 10.1016/j.neuroimage.2007.03.008.

Therapy of glioblastoma multiforme: a cumulative experience of 10 years.

Obwegeser A, Ortler M, Seiwald M, Ulmer H, Kostron H Acta Neurochir (Wien). 1995; 137(1-2):29-33.

PMID: 8748864 DOI: 10.1007/BF02188776.

Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.

Kruse C, Mitchell D, Kleinschmidt-DeMasters B, Bellgrau D, Eule J, Parra J J Neurooncol. 1993; 15(2):97-112.

PMID: 8509824 DOI: 10.1007/BF01053931.

Inhibition of tumor necrosis factor-alpha and -beta secretion by lymphokine activated killer cells by transforming growth factor-beta.

Naganuma H, Sasaki A, Satoh E, Nagasaka M, Nakano S, Isoe S Jpn J Cancer Res. 1994; 85(9):952-7.

PMID: 7961125 PMC: 5919594. DOI: 10.1111/j.1349-7006.1994.tb02974.x.

References

Grimm E, Ramsey K, Mazumder A, Wilson D, Djeu J, Rosenberg S . Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med. 1983; 157(3):884-97. PMC: 2186968. DOI: 10.1084/jem.157.3.884. View

George R, Loudon W, Moser R, Bruner J, Steck P, Grimm E . In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells. J Neurosurg. 1988; 69(3):403-9. DOI: 10.3171/jns.1988.69.3.0403. View

Bosnes V, Hirschberg H . Comparison of in vitro glioma cell cytotoxicity of LAK cells from glioma patients and healthy subjects. J Neurosurg. 1988; 69(2):234-8. DOI: 10.3171/jns.1988.69.2.0234. View

Jacobs S, Wilson D, Melin G, Parham C, HOLCOMB B, KORNBLITH P . Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies. Neurol Res. 1986; 8(2):81-7. DOI: 10.1080/01616412.1986.11739735. View

Grimm E, Mazumder A, Zhang H, Rosenberg S . Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982; 155(6):1823-41. PMC: 2186695. DOI: 10.1084/jem.155.6.1823. View

Shimizu K, Okamoto Y, Miyao Y, Yamada M, Ushio Y, Hayakawa T . Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. J Neurosurg. 1987; 66(4):519-21. DOI: 10.3171/jns.1987.66.4.0519. View

Jacobs S, Wilson D, KORNBLITH P, Grimm E . Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg. 1986; 64(5):743-9. DOI: 10.3171/jns.1986.64.5.0743. View

Rosenberg S, Lotze M, Muul L, Leitman S, Chang A, Ettinghausen S . Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985; 313(23):1485-92. DOI: 10.1056/NEJM198512053132327. View

Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S . A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316(15):889-97. DOI: 10.1056/NEJM198704093161501. View

10.

Jacobs S, Wilson D, KORNBLITH P, Grimm E . In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg. 1986; 64(1):114-7. DOI: 10.3171/jns.1986.64.1.0114. View

11.

Jacobs S, Wilson D, KORNBLITH P, Grimm E . Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 1986; 46(4 Pt 2):2101-4. View

12.

Okamoto Y, Shimizu K, Tamura K, Miyao Y, Yamada M, Matsui Y . An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien). 1988; 94(1-2):47-52. DOI: 10.1007/BF01406615. View